Table 3.

Summary of patients affected by respiratory-related adverse events

AEs classified as Respiratory, Thoracic and/or Mediastinal Disorders
	Placebo	AZD9164
GMAD, healthy subjects	n = 9	400 μg	1000 μg	2800 μg	Total (%)
		n = 6	n = 6	n = 6	n = 27
Throat irritation	1 (11.1)	0 (0)	1 (16.7)	2 (33.3)	4 (14.8)
Oropharyngeal pain	0 (0)	1 (16.7)	2 (33.3)	0 (0)	3 (11.1)
Cough	0 (0)	0 (0)	0 (0)	1 (16.7)	1 (3.7)
Dyspnoea	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.7)
JMAD, healthy subjects	n = 6	400 μg	1000 μg		Total (%)
		n = 6	n = 6		n = 18
Cough	0 (0)	1 (16.7)	1 (16.7)		2 (11.1)
Epistaxis	0 (0)	0 (0)	1 (16.7)		1 (5.6)
Nasal mucosal disorder	0 (0)	0 (0)	1 (16.7)		1 (5.6)
Respiratory tract infection	0 (0)	0 (0)	1 (16.7)		1 (5.6)
Upper respiratory tract infection	0 (0)	1 (16.7)	0 (0)		1 (5.6)
GMAD, COPD patients	n = 1		n = 3		n = 4
Dyspnoea	1 (100)		2 (66.7)		2 (50)
Cough	0 (0)		1 (33.3)		1 (25)